CROSSJECT SOCIÉTÉ ANONYME
ALCJ.PA
3.73
-0.05
(-1.32%)
Market Close
As on 26 Sep, 2023, 03:35 PM
Market Cap
149.18 M
P/E Ratio
-9.10
Div Yield
0.00%
Volume
72,834.00
Eps
-0.41
Previous Close
$3.78
Day Range
3.625 - 3.78
Year Range
2.625 - 5.0
Overall Rating
Strong Sell
Sell
Neutral
Buy
Strong Buy
Adocia SA
ADOC.PA
$6.51
Nanobiotix S.A.
NANO.PA
-5.65%
$8.16
Quantum Genomics Société Anonyme
ALQGC.PA
1.37%
$0.17
ABIONYX Pharma SA
ABNX.PA
3.12%
$1.15
Pharnext SA
ALPHA.PA
-0.35%
$1.10
AMA Corporation Plc
ALAMA.PA
-13.37%
$0.14
Theranexus Société Anonyme
ALTHX.PA
-2.86%
$1.16
Poxel S.A.
POXEL.PA
0.69%
$0.40
Oncodesign Société Anonyme
ALONC.PA
-20.59%
$14.42
Valbiotis SA
ALVAL.PA
0.00%
$5.32
Genkyotex SA
GKTX.PA
-5.34%
$3.21
Biosynex SA
ALBIO.PA
0.00%
$9.92
Visiomed Group SA
ALVMG.PA
-0.30%
$0.38
Eurofins-Cerep SA
ALECR.PA
-1.41%
$29,200.00
Hybrigenics SA
ALHYG.PA
3.55%
$0.06
Biophytis S.A.
ALBPS.PA
-0.18%
$0.01
Pixium Vision SA
ALPIX.PA
-16.67%
$1.65
Celyad Oncology SA
CYAD.BR
-5.53%
$0.70
-7.92%
No data
No data
|
Date
|
Consensus EPS
|
Eps
|
Consensus Revenue
|
Revenue
|
|---|---|---|---|---|
|
Sep 25
|
N/A | N/A | 10.95 M | N/A |
|
Sep 22
|
N/A | N/A | 10.95 M | N/A |
|
Sep 21
|
N/A | N/A | 10.95 M | N/A |
|
Sep 19
|
N/A | N/A | 10.95 M | N/A |
|
Sep 18
|
N/A | N/A | 10.95 M | N/A |
|
Sep 17
|
N/A | N/A | 10.95 M | N/A |
ALCJ.PA Profile
Industry:
Medical Instruments & Supplies
Sector:
Healthcare
CEO:
Mr. Patrick Alexandre
Exchange:
Euronext
Paris
Crossject Société Anonyme develops needle-free injection systems. The company develops ZENEO, a needle-free, prefilled, and single-use auto-injector. Its clinical stage drugs comprise Sumatriptan, which is used for of treatment migraines and cluster headaches; Adrenaline for treating anaphylactic shock; Hydrocortisone that is used for treatment of acute adrenal crisis; Midazolam for treating epileptic seizure; Naloxone used for treatment of overdose; Apomorphine, for treating temporary paralysis in parkinson's disease; Methotrexate used for treatment of rheumatoid arthritis; and Terbutaline, for treating severe asthma crisis. The company was founded in 1997 and is based in Dijon, France.